Literature DB >> 17302559

Exploring the specificity of the PI3K family inhibitor LY294002.

Severine I Gharbi1, Marketa J Zvelebil, Stephen J Shuttleworth, Tim Hancox, Nahid Saghir, John F Timms, Michael D Waterfield.   

Abstract

The PI3Ks (phosphatidylinositol 3-kinases) regulate cellular signalling networks that are involved in processes linked to the survival, growth, proliferation, metabolism and specialized differentiated functions of cells. The subversion of this network is common in cancer and has also been linked to disorders of inflammation. The elucidation of the physiological function of PI3K has come from pharmacological studies, which use the enzyme inhibitors Wortmannin and LY294002, and from PI3K genetic knockout models of the effects of loss of PI3K function. Several reports have shown that LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. Since this inhibitor still remains a drug of choice in numerous PI3K studies (over 500 in the last year), it is important to establish the precise specificity of this compound. We report here the use of a chemical proteomic strategy in which an analogue of LY294002, PI828, was immobilized onto epoxy-activated Sepharose beads. This affinity material was then used as a bait to fish-out potential protein targets from cellular extracts. Proteins with high affinity for immobilized PI828 were separated by one-dimensional gel electrophoresis and identified by liquid chromatography-tandem MS. The present study reveals that LY294002 not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17302559      PMCID: PMC1868829          DOI: 10.1042/BJ20061489

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  51 in total

Review 1.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

2.  An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

Authors:  Klaus Godl; Josef Wissing; Alexander Kurtenbach; Peter Habenberger; Stephanie Blencke; Heidrun Gutbrod; Kostadinos Salassidis; Matthias Stein-Gerlach; Andrea Missio; Matt Cotten; Henrik Daub
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

3.  The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis.

Authors:  Anup Dey; Farideh Chitsaz; Asim Abbasi; Tom Misteli; Keiko Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-02       Impact factor: 11.205

4.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

Review 5.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

6.  Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization.

Authors:  Andrea Farina; Masakazu Hattori; Jun Qin; Yoshihiro Nakatani; Nagahiro Minato; Keiko Ozato
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

7.  Genomic organization, tissue distribution and deletion mutation of human pyridoxine 5'-phosphate oxidase.

Authors:  Jeong Han Kang; Mi-Lim Hong; Dae Won Kim; Jinseu Park; Tae-Cheon Kang; Moo Ho Won; Nam-In Baek; Byung Jo Moon; Soo Young Choi; Oh-Shin Kwon
Journal:  Eur J Biochem       Date:  2004-06

8.  PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues.

Authors:  Belinda M Abbott; Philip E Thompson
Journal:  Bioorg Med Chem Lett       Date:  2004-06-07       Impact factor: 2.823

9.  LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism.

Authors:  Eun-Kyoung Choi; Hyun-Ju Park; Jae-Sook Ma; Hyun-Chul Lee; Ho-Cheol Kang; Byung-Gook Kim; In-Chol Kang
Journal:  FEBS Lett       Date:  2004-02-13       Impact factor: 4.124

10.  Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains.

Authors:  Yihong Ye; Hemmo H Meyer; Tom A Rapoport
Journal:  J Cell Biol       Date:  2003-07-07       Impact factor: 10.539

View more
  165 in total

Review 1.  Utility of mTOR inhibition in hematologic malignancies.

Authors:  Anas Younes; Nousheen Samad
Journal:  Oncologist       Date:  2011-05-31

Review 2.  The role of targeted chemical proteomics in pharmacology.

Authors:  Chris W Sutton
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Single Cell Chemical Cytometry of Akt Activity in Rheumatoid Arthritis and Normal Fibroblast-like Synoviocytes in Response to Tumor Necrosis Factor α.

Authors:  Emilie R Mainz; D Stephen Serafin; Tuong T Nguyen; Teresa K Tarrant; Christopher E Sims; Nancy L Allbritton
Journal:  Anal Chem       Date:  2016-07-20       Impact factor: 6.986

4.  Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.

Authors:  Susann Herzog; Matthias Alexander Fink; Kerstin Weitmann; Claudius Friedel; Stefan Hadlich; Sönke Langner; Katharina Kindermann; Tobias Holm; Andreas Böhm; Eskil Eskilsson; Hrvoje Miletic; Markus Hildner; Michael Fritsch; Silke Vogelgesang; Christoph Havemann; Christoph Alexander Ritter; Henriette Elisabeth Meyer zu Schwabedissen; Bernhard Rauch; Wolfgang Hoffmann; Heyo Klaus Kroemer; Henry Schroeder; Sandra Bien-Möller
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

Review 5.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

6.  mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.

Authors:  Stefan Thiem; Thomas P Pierce; Michelle Palmieri; Tracy L Putoczki; Michael Buchert; Adele Preaudet; Ryan O Farid; Chris Love; Bruno Catimel; Zhengdeng Lei; Steve Rozen; Veena Gopalakrishnan; Fred Schaper; Michael Hallek; Alex Boussioutas; Patrick Tan; Andrew Jarnicki; Matthias Ernst
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

7.  A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock.

Authors:  M Piccioni; C Monari; S Kenno; E Pericolini; E Gabrielli; D Pietrella; S Perito; F Bistoni; T R Kozel; A Vecchiarelli
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

Review 8.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

9.  rna interference targeting p110β reduces tumor necrosis factor-alpha production in cellular response to wear particles in vitro and osteolysis in vivo.

Authors:  Jian-bin Huang; Yue Ding; Dong-sheng Huang; Wei-ke Zeng; Zhi-ping Guan; Mao-lin Zhang
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

Review 10.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.